Jul 10, 2018
Identifying functional molecules with the potential to be developed into new therapeutics is often the sole aim of phenotypic drug discovery.
However, the approach also provides valuable opportunities to uncover previously unknown, disease-specific drug receptors that can then be exploited through target driven means. Although target deconvolution has a reputation as a major bottleneck in phenotypic drug development, advances allowing for rapid identification of specific receptors for both biologics and small molecules are increasing the pace of phenotypic drug discovery while also providing access to the significant IP generated by the discovery of novel drug targets.
This article was written by Dr Jim Freeth, Dr Elizabeth Kingsley, & Jo Soden, all of Retrogenix
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: